Based on the Gram-negative type III secretion apparatus, required for pathogenesis, a prophylactic vaccine to prevent acute pneumonia caused by Pseudomonas aeruginosa, was developed for use in immunocompromised individuals such as the elderly, those with cystic fibrosis and other respiratory ailments. Recently, it has been identified as a therapeutic vaccine in a cystic fibrosis rat model. Along with the antibiotic, tobramycin, the vaccine can clear a previously developed chronic Pseudomonas aeruginosa infection in these rats.
Learning Objectives:
Upon completion, participants will be able to understand how bacterial surface proteins can be used as protective antigens.
Upons completion, participants will be able to understand the advantage of a nanoemulsion formulation.
Upon completion, participants wil be able to understand the advantage of using a mucosal vaccine delivery site to elicit a mucosal immune response.
Upon completion, participants will be able to understand how a prophylactic vaccine can be filled to a therapeutic vaccine.
